Fatty liver disease has quietly become one of the world’s most common chronic health conditions.
As obesity, type 2 diabetes, and metabolic disorders continue to rise, doctors are seeing increasing numbers of patients develop liver damage caused by excess fat accumulation. Unfortunately, many people do not discover the problem until the disease has already progressed.
A new study published in The Lancet offers hope that a novel treatment could help change that. Researchers from the University of California San Diego School of Medicine have reported positive results from a clinical trial involving an experimental drug called ION224.
The treatment appears to attack one of the main drivers of liver damage and may eventually become an important new option for patients with metabolic dysfunction-associated steatohepatitis, or MASH.
MASH is the more severe form of a broader condition known as metabolic dysfunction-associated steatotic liver disease. In simple terms, it occurs when too much fat builds up in the liver and triggers ongoing inflammation.
Over time, this inflammation can injure liver cells and lead to the development of scar tissue. As scarring worsens, liver function gradually declines.
One reason MASH is so concerning is that it often develops silently. Many people feel perfectly healthy during the early stages. By the time symptoms appear, substantial liver damage may already have occurred. This makes early treatment especially important.
Current approaches typically focus on lifestyle changes such as weight loss, healthier eating, and increased physical activity. These strategies can be effective, but they are not always sufficient, and many patients struggle to achieve the level of weight loss needed to significantly improve liver health.
As a result, researchers have been eager to develop medications that directly target the disease process.
ION224 was designed with this goal in mind. The drug blocks an enzyme known as DGAT2, which plays a central role in producing and storing fat within the liver.
Scientists believe that excessive fat accumulation is one of the earliest events that leads to inflammation, fibrosis, and long-term liver damage. By interrupting this process, the drug aims to prevent disease progression at its source.
To evaluate the treatment, researchers conducted a Phase IIb clinical trial involving 160 adults with MASH and mild to moderate fibrosis. Participants received monthly injections of ION224 or a placebo over a period of 51 weeks. Researchers then measured changes in liver health, inflammation, and fibrosis.
The results suggested that the treatment had meaningful biological effects. Patients receiving the highest dose showed some of the strongest improvements. Approximately 60 percent experienced significant improvements in liver-related outcomes compared with placebo-treated participants.
One of the most interesting findings was that improvements occurred even in the absence of major weight loss. This suggests the drug may work directly within the liver rather than relying primarily on changes in body weight. Such an effect could make it useful for a broader range of patients, including those who have difficulty losing weight despite medical advice.
Safety is always a major concern in drug development, particularly for chronic diseases that may require long-term treatment. According to the researchers, ION224 was generally well tolerated and did not produce serious treatment-related side effects. The drug also avoided certain complications observed with some other therapies designed to reduce liver fat.
Researchers view the findings as particularly important because this is the first study demonstrating that blocking DGAT2 through an antisense approach can improve both inflammation and fibrosis in patients with MASH.
Since fibrosis is one of the strongest predictors of serious liver complications, reducing scar tissue is considered a major treatment goal.
Looking ahead, scientists believe the future of MASH treatment may involve combination therapies. Patients could potentially receive liver-specific drugs such as ION224 alongside medications that target obesity, diabetes, or insulin resistance. Combining these approaches may provide greater benefits than any single treatment alone.
Source: University of California San Diego School of Medicine.
